Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer
Reason given: Terminated Early
Key facts
- Where
- Dallas, La Jolla, Lake Mary, Saint Louis Park, Saint Paul, Tampa, and Washington D.C., United StatesSee the 7 sites
- Phase
- Phase 2
Where in United States
- Mary Crowley Cancer ResearchDallas, United StatesNo longer taking part
- UC San Diego Health Moores Cancer CenterLa Jolla, United StatesNo longer taking part
- Florida Cancer Specialists & Research Institute (FCS)Lake Mary, United StatesNo longer taking part
- HealthPartners Frauenshuh Cancer CenterSaint Louis Park, United StatesNo longer taking part
- HealthPartners Cancer Center at Regions HospitalSaint Paul, United StatesNo longer taking part
- Tampa General Hospital - Cancer Center of South FloridaTampa, United StatesNo longer taking part
- Georgetown University Medical Center - Lombardi Comprehensive Cancer CenterWashington D.C., United StatesNo longer taking part
Trial details
- Who runs it
- Sutro Biopharma, Inc.
- Trial code
- NCT06555263
- Record updated
- 22 August 2025
- Original description
A Phase 2 study evaluating STRO-002 in subjects with previously treated advanced or metastatic non-small cell lung cancer expressing FOLR1Read full original descriptionShow less
A Phase 2, Open-label Study Evaluating STRO-002, an Anti-folate Receptor Alpha (FOLR1) Antibody-Drug Conjugate, in Subjects With Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Expressing FOLR1
A Phase 2 study evaluating STRO-002 in subjects with previously treated advanced or metastatic non-small cell lung cancer expressing FOLR1
Inclusion: Histologically or cytologically confirmed non-squamous/adenocarcinoma or adenosquamous NSCLC that is either unresectable Stage IIIb/c disease not amenable for definitive chemoradiation, or Stage IV; Age ≥ 18 years; ECOG performance status 0 to 1; Received at least 2 but no more than 4 prior lines of systemic therapy for advanced NSCLC; Disease progression during or following the most recent systemic anti-cancer therapy; Positive FOLR1 expression per central testing; At least 1 measurable target lesion per RECIST 1.1; Adequate organ function.
Exclusion: Prior treatment with a FOLR1- targeting ADCs or with ADCs that contain a tubulin inhibitor; Ongoing immunosuppressive therapy, except for treated brain metastases, per criterion above; Pre-existing clinically significant ocular disorders, severe chronic obstructive pulmonary disease or asthma, clinically significant cardiac or cerebrovascular disease, or other significant concurrent, uncontrolled medical condition; Previous solid organ transplantation; Concurrent participation in another therapeutic treatment trial; History of severe allergic or anaphylactic reactions to monoclonal antibody therapy or to antibody-related fusion protein treatment; Untreated central nervous system metastases.